|
IQVIA™ Real-World Insights Bibliography
| Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study |
| Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
|
| Affiliations(s): "1
Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel
2
Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
3
German Centre for Diabetes Research (DZD), München-Neuherberg, Germany
4
Department of Health Service Administration, China Medical University, Taichung, Taiwan
5
Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan
6
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
7
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
8
Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan
9
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
10
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
11
Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK
12
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
13
Midlands Health Data Research UK, Birmingham, UK
14
DEMAND Hub, University of Birmingham, Birmingham, UK
15
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden
16
Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland
17
IQVIA Solutions Denmark A/S, Copenhagen, Denmark
18
IQVIA, Espoo, Finland
19
IQVIA, Tartu, Estonia
20
Boehringer Ingelheim International GmbH, Ingelheim, Germany
21
Boehringer Ingelheim International GmbH, US
22
Lilly Deutschland GmbH, Bad Homburg, Germany
23
Steno Diabetes Center Copenhagen, Herlev, Denmark
24
Department of Public Health, University of Copenhagen, Copenhagen, Denmark
25
Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway
26
Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
27
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
28
Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" |
Publication(s): "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636
Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
|
| Document Type(s): Article, |
| Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, |
|
 |
| |
| |
| The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
|
| Author(s): Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens
Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore,
Aida Aydemir, Irene Bezemer & Meritxell Sabidó
|
| Affiliations(s): "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia;
b The Alfred Hospital, Melbourne, VIC, Australia;
c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;
d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland;
e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany;
f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland;
g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland;
h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway;
i Department of Clinical Medicine, University of Bergen, Bergen, Norway;
j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
l Bordeaux PharmacoEpi (BPE), Universit?e de Bordeaux, Bordeaux, France;
m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA;
n Global Epidemiology, IQVIA, Amsterdam, The Netherlands;
o Merck Healthcare KGaA, Darmstadt, Germany"
|
| Publication(s): |
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders,
2023 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Population Based Study, |
|
|
| |
| |
| Burden of Hospitalizations and Outpatient Visits Associated With Moderate and Severe Acute Graft-Versus-Host Disease in Finland and Sweden: A Real-World Data Analysis |
| Author(s): Lorenzo Sabatelli, PhD,1 Mikko Keränen, MD, PhD,2 Elisabet Viayna, PhD,3 Montserrat Roset, BSc Stats,3 Nuria Lara, MD, MSc,3 Daniel Thunström, MSc Pharm,1 Minja Pfeiffer, PhD,1 Malin Nicklasson, MSc Pharm,4 Maija Itälä-Remes, MD, PhD5
|
| Affiliations(s): "1Incyte Biosciences International Sàrl, Morges, Switzerland; 2Helsinki University Hospital, Helsinki, Finland; 3IQVIA Real World Solutions, Barcelona, Spain; 4Department of Hematology and Coagulation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 5Turku University Hospital, Turku, Finland "
|
Publication(s): Supportive Care in Cancer
|
| Document Type(s): Article, |
| Countries: Finland, Spain, Sweden, Switzerland, |
C:
Y: |
Health economics, Transplant,
2022 |
|
L:
A: |
English
Clinical setting: hospital, Observational study, Population Based Study, |
|
|
| |
| |
| The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets |
| Author(s): Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group |
| Affiliations(s): 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
2The Alfred Hospital, Melbourne, Australia.
3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France.
4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA).
5Global Database Studies, IQVIA, Tartu, Estonia.
6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands.
7IQVIA (former EPID Research), Espoo, Finland.
8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. |
Publication(s): Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977
|
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Drug safety, Neurological disorders,
2022 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| Treatment Patterns, Socioeconomic Status and Clinical Burden in Mild COPD: A Swedish Real-World, Retrospective Cohort Study, the ARCTIC Study |
| Author(s): Kjell Larsson,1 Karin Lisspers,2 Björn Ställberg,2 Gunnar Johansson,2 Florian S Gutzwiller,3 Karen Mezzi,3 Bine Kjoeller Bjerregaard,4 Leif Jorgensen,4 Hyewon Koo,5 Christer Janson6 |
| Affiliations(s): 1Integrative Toxicology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 2Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 3Novartis Pharma AG, Basel, Switzerland; 4IQVIA Solutions, Copenhagen, Denmark; 5IQVIA Solutions, Solna, Sweden; 6Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden |
Publication(s): International Journal of Chronic Obstructive Pulmonary Disease 2022:17 1409?1421 https://doi.org/10.2147/COPD.S364932
PMID 35761954
|
| Document Type(s): Article, |
| Countries: Sweden, |
| Click here for the abstract |
C:
Y: |
Respiratory disease,
2022 |
|
L:
A: |
English
Clinical setting: Primary care, Epidemiological study, Population Based Study, Real World Data, Retrospective cohort analysis, |
|
|
| |
| |
| Validation of safety outcomes in routinely collected data: lessons learned from a multinational post-approval safety study
|
| Author(s): Arena PJ, Huang K, Löfling L, Bahmanyar S, Mo J, Schachterle SE, Nunes AP, Smits E, Juuti R, Hoti F, Korhonen P, Adelborg K, Sundbøll J, Rasmussen TR, Løkke A, Ehrenstein V.
|
| Affiliations(s): "Pfizer Inc., New York, New York, United States of America.
Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California, United States of America.
EPID Research (an IQVIA company), Espoo, Finland."
|
Publication(s): Pharmacoepidemiol Drug Saf. 2022 Dec 10. doi: 10.1002/pds.5582
|
| Document Type(s): Article, |
| Countries: Denmark, Finland, Netherlands , Sweden, USA, |
| Click here for the abstract |
C:
Y: |
Database Validity and methodology, Drug safety, Oncology,
2022 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Retrospective database analysis, |
|
|
| |
| |
| Predicting Hospitalization Due to COPD Exacerbations in Swedish Primary Care Patients Using Machine Learning ? Based on the ARCTIC Study |
| Author(s): Björn Ställberg 1, Karin Lisspers 1, Kjell Larsson 2, Christer Janson 3, Mario Müller 4, Mateusz Łuczko 5, Bine Kjøller Bjerregaard 6, Gerald Bacher 7, Björn Holzhauer 7, Pankaj Goyal 7, Gunnar Johansson 1 |
| Affiliations(s): 1Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden.
2Integrative Toxicology, Karolinska Institutet, Stockholm, Sweden.
3Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
4Department of Data Science and Advanced Analytics, IQVIA, Frankfurt Am Main, Germany.
5Department of Data Science and Advanced Analytics, IQVIA, Warsaw, Poland.
6Department of Real World Evidence Solutions, IQVIA, Copenhagen, Denmark.
7Department of Clinical Development and Analytics, Novartis Pharma AG, Basel, Switzerland. |
Publication(s): Journal: Int J Chron Obstruct Pulmon Dis. 2021 Mar 16;16:677-688. doi: 10.2147/COPD.S293099. eCollection 2021.
Conference: IPCRG, Dublin, Ireland, Weekly series of Clinical Practice Webinars - Various Saturdays from 16th May to 27th June 2020
PMID: 33758504 PMCID: PMC7981164 DOI: 10.2147/COPD.S293099
|
| Document Type(s): Article, |
| Countries: Sweden, |
| Click here for the abstract |
C:
Y: |
Respiratory disease,
2021 |
|
L:
A: |
English
Epidemiological study, Population Based Study, |
|
|
| |
| |
| Developing a short-term prediction model for asthma exacerbations from Swedish primary care patients? data using machine learning - based on the ARCTIC study Respiratory Medicine |
| Author(s): Karin Lisspers a,*, Bj¨orn St¨allberg a, Kjell Larsson b, Christer Janson c, Mario Müller d,
Mateusz Łuczko e, Bine Kjøller Bjerregaard f, Gerald Bacher g, Bj¨orn Holzhauer g, Pankaj Goyal g,
Gunnar Johansson a |
| Affiliations(s): a Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden
b Integrative Toxicology, Karolinska Institutet, Stockholm, Sweden
c Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden
d IQVIA, Frankfurt am Main, Germany
e IQVIA, Warsaw, Poland
f IQVIA, Copenhagen, Denmark
g Novartis Pharma AG, Basel, Switzerland |
| Publication(s): |
| Document Type(s): |
| Countries: Sweden, |
| Click here for the abstract |
C:
Y: |
Respiratory disease,
2021 |
|
L:
A: |
English
Clinical setting: Primary care, clinical setting: Secondary care, Predictive analytics, |
|
|
| |
| |
| Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden
|
| Author(s): Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5
|
| Affiliations(s): 1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA
|
Publication(s): ECTRIMS 2021, Digital, 13-15 October 2021
|
| Document Type(s): Abstract, |
| Countries: Finland, Sweden, |
| Click here for the abstract |
C:
Y: |
Drug Utlization Study, Neurological disorders,
2021 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden
|
| Author(s): Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5
|
| Affiliations(s): 1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA
|
Publication(s): ECTRIMS 2021, Digital, 13-15 October 2021
|
| Document Type(s): Poster, |
| Countries: Finland, Sweden, |
| Click here for the abstract |
C:
Y: |
Drug Utlization Study, Neurological disorders,
2021 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
 1 of 22 
|
|
